Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium

Phase 2 Completed 115 enrolled Allergan

RandomizedParallel-groupTriple-blindTreatment

Summary

This study will evaluate the safety and efficacy of Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®) in patients with primary pterygium (abnormal growth on surface of eye).

Timeline

Start: 2010-06
Primary completion: 2011-05
Completion: 2011-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cyclosporine	Peptide	0.05 %	—

Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium

Summary

Timeline

Drugs

Indications